Effect of teriparatide on improving fracture union in osteoporotic intertrochanteric fractures: A systematic review and meta-analysis

Table 2 Publication data and major demographic characteristics of the included studies

Ref.	Country	Type of study	Patients, n		Other patient parameters		Follow-up duration		Teriparatide injection parameters: Dose, route, and duration of administration	Control modality parameters: Dose, route, and duration of administration
			Teriparatide group	Control group	Teriparatide group	Control group	Teriparatide group	Control group
Huang et al[21]	Taiwan	Retrospective	47	83	BMD: -4.2 ± 1.3	BMD: -3.9 ± 1.2	Minimum of 12 months	Minimum of 12 months	20 μg/day subcutaneously usually for 18 months (minimum of 12 months) beginning on the day of surgery	None
Kim et al[22]	South Korea	Retrospective	52	60	BMD: -3.4 (-4.9 to -2.8)	BMD: -3.2 (-5.2 to -2.9)	Minimum follow-up was 10 months (average: 1.6 years; range: 0.8-3.0 years)	Minimum follow-up was 10 months (average: 1.6 years; range: 0.8-3.0 years)	20 μg/day subcutaneously for 2 months	None
Rana et al[23]	India	RCT	15	15	BMD (kg/m2): 0.537 ± 0.073	BMD (kg/m2): 0.561 ± 0.081	6 months	6 months	20 μg/day subcutaneously for 6 months	None
Mishra et al[24]	India	RCT	16	15	BMD of all patients < -2.5	BMD of all patients < -2.5	24 weeks	24 weeks	20 μg/day subcutaneously for 24 weeks	None
Aggarwal et al[26]	India	RCT	20	20	BMD: -3.04 ± 0.43	BMD: -3.17 ± 0.73	6 months (24 weeks)	6 months (24 weeks)	20 μg/day subcutaneously for 24 weeks	None
Tanavalee et al[25]	Thailand	RCT	25	25	BMD (g/cm3): Total hip: 0.631 ± 0.211; femoral neck: 0.518 ± 0.156	BMD (g/cm3): Total hip: 0.598 ± 0.220; femoral neck: 0.517 ± 0.201	24 weeks	24 weeks	20 μg/day subcutaneously for 24 weeks	Normal saline

RCT: Randomized controlled trial; BMD: Bone mineral density.